- Condition: Multiple Sclerosis
Interventions: Drug: PR Fampridine; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: Warfarin; Drug: Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: University at Buffalo; University at Buffalo; Biogen Idec; Jacobs Neurological Institute; Department of Neurology and Center of Clinical Neuroscience and; Department of Radiology, Charles University in Prague, First Faculty; of Medicine, Prague, Czech Republic
Active, not recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Natalizumab (Tysabri)
Sponsors: Cornerstone Health Care, PA; Cornerstone Health Care, PA; Biogen Idec
Recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: Standard dose BG00012; Drug: Aspirin placebo; Drug: Aspirin; Drug: Escalating doses of BG00012; Drug: BG00012 placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Cimetidine plus Dexpramipexole
Sponsors: Biogen Idec; Biogen Idec
Completed - verified May 2012 - Condition: Lymphoma
Interventions: Drug: Y Zevalin; Drug: In Zevalin; Drug: Rituxan; Drug: BCNU; Drug: VP -16; Drug: Ara-C; Drug: Melphalan; Procedure: Stem Cell Infusion; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Biogen Idec
Completed - verified February 2012 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Dexpramipexole; Drug: Dexpramipexole Placebo; Drug: Moxifloxacin
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified January 2012 - Condition: Multiple Sclerosis (Relapsing Remitting)
Interventions: Behavioral: Training; Behavioral: Control
Sponsors: University of Aarhus; University of Aarhus; Sport Science, Institute of Public Health, Aarhus University; Department of Neurology, Aarhus University Hospital, NBG; MR-Research Centre, Aarhus University Hospital, Skejby; Department of Endocrinology, Aarhus University Hospital, NBG; Biogen Idec
Recruiting - verified February 2012 - Condition: Multiple Sclerosis
Interventions: Drug: Interferon beta-1a (current approved manufacturing process invloving FBS); Drug: Interferon beta-1a (new process, manufactured without FBS)
Sponsors: Biogen Idec; Biogen Idec
Completed - verified May 2012 - Conditions: Multiple Sclerosis; Pregnancy
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified February 2012 - Condition: Relapsing-remitting Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified March 2012 - Condition: Lupus Nephritis
Interventions: Drug: BIIB023; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Biogen Idec Australia Pty Ltd; Biogen Idec Research Ltd.; Biogen Idec MA Inc.
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention: Drug: Fampridine
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012 - Condition: Hemophilia A
Intervention: Drug: rFVIIIFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum; Biogen Idec MA Inc.
Not yet recruiting - verified March 2012 - Condition: Multiple Sclerosis
Interventions: Other: clinical and neurological evaluation; Other: Blood Sample; Genetic: Blood Sample
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012 - Condition: Healthy
Interventions: Drug: BG00012 Dose 1; Drug: BG00012 Dose 2
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified March 2012 - Condition: Hemophilia A
Intervention: Drug: rFVIIIFc
Sponsors: Biogen Idec; Biogen Idec
Not yet recruiting - verified November 2011 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Dexpramipexole; Drug: Dexpramipexole Placebo
Sponsors: Biogen Idec; Biogen Idec
Completed - verified January 2012 - Condition: Hemophilia B
Intervention: Drug: rFIXFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum
Recruiting - verified May 2012 - Condition: Severe Hemophilia B
Intervention: Drug: rFIXFc
Sponsors: Biogen Idec; Biogen Idec; Swedish Orphan Biovitrum
Not yet recruiting - verified December 2011 - Condition: Healthy Volunteers
Intervention: Drug: Experimental
Sponsors: Biogen Idec; Biogen Idec
Completed - verified November 2011 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified April 2012 - Condition: Amyotrophic Lateral Sclerosis
Interventions: Drug: Single dose reduced; Drug: Single dose standard; Drug: Multiple Dose; Drug: Multiple Dose
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012 - Condition: Sciatica
Interventions: Drug: BG00010; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified September 2011 - Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec; Elan Pharmaceuticals
Recruiting - verified March 2012 - Condition: Relapsing Remitting Multiple Sclerosis
Intervention: Biological: Daclizumab High Yield Process prefilled syringe
Sponsors: Biogen Idec; Biogen Idec; Abbott Biotherapeutics Corp.
Recruiting - verified April 2012 - Condition: Relapsing Multiple Sclerosis
Interventions: Drug: Natalizumab; Drug: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified December 2011 - Condition: Healthy Volunteers
Interventions: Drug: BIIB023 - low dose IV Dose; Drug: BIIB023 - high dose IV Dose
Sponsors: Biogen Idec; Biogen Idec
Completed - verified March 2012 - Condition: Alzheimer's Disease
Interventions: Drug: BIIB037; Other: Placebo
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified July 2011 - Condition: Healthy
Intervention: Drug: Avonex
Sponsors: Biogen Idec; Biogen Idec
Completed - verified November 2011 - Conditions: Amyotrophic Lateral Sclerosis; Renal Insufficiency
Interventions: Drug: Dexpramipexole (dose 1); Drug: Dexpramipexole (dose 2)
Sponsors: Biogen Idec; Biogen Idec
Completed - verified January 2012 - Condition: Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Active, not recruiting - verified March 2012


